CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

Figure 2

Promising treatment combinations of anti-CD47 drugs and current effective therapies for NSCLC. The inhibition of the CD47-SIRPα axis with anti-CD47 mAb can induce antitumor immunity through various mechanisms. Combining anti-CD47 with TKIs might be beneficial for two reasons. First, EGFR inhibition has shown to significantly reduce CD47 expression. Second, the inhibition of CD47 could increase the clearance of TKI-resistant cells. Combining anti-CD47 with antiangiogenic therapy could likewise be useful, since CD47 blockade could sensitize NSCLC to the latter therapy and potentiate its antitumor effects.